U.S. Department of Commerce Patent and Trademark Office				Atty, Docket No. 22335-US Serial No. 10/575,600							
· LIST OF INFORMATION CITED BY APPLICANT (Use several short)					Applicants: Martin Dugas, et al.						
SEP 1.5 1005 m				International Filing Date: Nov 4, 2004			004	Group: N/A			
\		5-71	······································		·····		<u> </u>	•••••	••••		
* EXAMINER	188	MOS CUMENT NUMBER	U.S. PA		DOCUMENTS NAME	CLAS	s sum	CLASS	FILING	DATE	
INITIAL		Coccomican Incomocia							IF APPR	OPRIATE	
	1	5,210,015	05/11/93		Gelfand, et al	435		6	08/0	6/90	
	2	5,445,934	08/29/95		Fodor, et al	435		6	09/3	0/92	
3	3	5,487,972	01/30/96	*******************************	Gelfand, et al	435		6	01/0	5/93	
	4	5,700,637	12/23/97		E. Southern	435		6	04/1	9/94	
	5	5,744,305	04/28/98	•	Fodor, et al	435		6	06/0	6/95	
; <b>¥</b>	6	5,804,375	09/08/98		Gelfand, et al	435		6	04/2	5/95	
	7	5,945,334	08/31/99		Besemer, et al	435	28	37.2	06/0	7/95	
:	8	6,174,670 B1	01/16/01		Wittwer, et al	435		6	06/0	14/97	
	ÿ	2003/0138793 A1	07/24/03	<del></del>	Su, et al	435		6	06/1	0/02	
•••••	<b></b>						····	************			
		F	OREIGN	PATE	NT DOCUMENTS						
		DOCUMENT NUMBER	PUBLIC/ DAT		COUNTRY	CLASS	SUBC	LASS	TRANSI	ATION	
	10	0 373 203 81	08/31/94		EP			***************************************		,	
:	11	0 619 321 81	01/07/90		EP						
	12	1 043 676 A1	10/11/00		EP						
	13	1 109 020 A1	06/20/200	1	EP						
······	14	WO 92/02638	02/20/92		PCT			<del></del>			
	15	WO 03/039443 A2	05/15/03		PCT			***************************************			
	16	WO 2005/04316 A3	05/12/05	***************************************	PCT						
	17	EP 2004/012470 Search Report	06/24/06	andersen of energy of a second debate	PCT						
	**********	OTHER ART (In	cluding A	uthor.	Title, Date, Pertin	ent Pace	s. Etc.)	***************************************	<del></del>		
	18	Alizadeh, A., et al., 1999, "I Gene Expression in Norma Biology, Volume LXIV, Coi	The Lymphol l and Malig	chip: A nant Lyr	Specialized cDNA Mi nphocytes", Cold Spri	croarray fo ngs Harbo	or the Geno	mic-sca um on Q	le Analysi Juantitativ	s of re	
	19		i, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector nes, PNAS, 97(1):262-267								
	20	1	2003, "Evolutionary algorithms for finding optimal gene sets in microarray prediction", Bioinformatics,								
	21	Dugas, M., et al., 2001, "A o microarray data with clinic	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and nicroarray data with clinical information; cytomorphology and immunophenotyping", Leukemia, 15:1805-1810								
	ZALDBEPERENDESOONBIDEREDIEXOEPTONHERELINEDITHROUGH. /SA										

Attorney Docket: 22335-US Serial No. 10/575,600

Page 2 of 2

SEP 1	1006							
, w.m.		I falled by T						
A Temat	1	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 286:531-537						
	25	aferlach, T., et al., "Abstract: The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene apression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", Blood, 100, Abstract 523						
	26	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory						
	27	Kiyoi, H., et al., 2002, "FLT3 in Human Hematologic Malignancies", Leukemia and Lymphoma, 43(8):1541-1547						
	28	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature. 256:495-497						
	29	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", Blood, 100, Abstract 4287						
4	30	Kottaridis K., et al., 2001, "Abstract: Changes in the pattern of FLT3 mutations between diagnosis and relapse restricts the potential use as markers of minimal residual disease in patients with acute myeloid leukaemia", Blood, 98(11-1):717a-718a						
,	31	Lacayo, N., et al., 2002, "Abstract: Gene Expression Profiling of Pediatric Acute Myeloid Leukemia (AML) in De Novo and Relapsed Patients Reveals an Expression Signature That correlates with FLT3-Internal Tandem duplications (ITD), FLT3 Point Mutations, and KIT Point Mutations", Blood, 100, Abstract 310						
<b>*</b>	32	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", Nucleic Acids Research, 31(1):82-86						
	Neben, K., et al., 2002, "Acute Myeloid Leukemia with Normal Karyotype and Mutation of the FLT3 or M Are Characterized by Specific Gene Expression Profiles", Blood, 100, Abstract 2172							
	34	Nigro, C., et al., 2001, "Internal Tandem Duplication and D385 Mutation Analysis of FLT3 Gene in AML Patients", Blood, 98:11- Part 2, pp 190b						
	35 Schnittger, S., et al., 2002, "Networks of Molecular Mutations in Acute Myeloid Leukemia and Their Correla cytogenetics and Morphology", Blood, 100, Abstract 735							
	36	Schnittger, S., et al., 2002, "Acute Myeloid Leukemia (AML) with FLT3-Length Mutations (FLT3-LM) Can Be Discriminated from AML without FLT3-LM in Distinct AML-Subtypes Based on Specific Gene Expression Profiles", Blood, 100, Abstract 1203						
	37	Storey, J., et al., 2003, "Statistical significance for genomewide studies," PNAS, 100(16):9440-9445						
EXAMINER		DATE CONSIDERED						

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Sean Aeder/ (02/19/2008)